Clinical trials: COVID-19 Vaccine
Healthy
Convalescent Plasma Donor Vaccine Study An Observational Antibody Level Study.
There is a need to understand antibody responses following SARS-COV-2 infection and subsequent vaccination.
- Trial name
- C-VELVET (NCT04954937)
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- NHS Blood and Transplant
COVID-19 Vaccine
Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults
Part I: 12 subjects will receive an open-label 500 µl subcutaneous injection via needle and syringe of the study IMP (CoVac-1). No more than one subject per day will be enrolled.
- Trial name
- pVAC (NCT04546841)
- Testing
- multipeptide cocktail
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
COVID-19
Effectiveness of Inactivated COVID-19 Vaccine of the First Booster Dose
This is a retrospective test-negative case-control study of COVID-19 Vaccine (CoronaVac®) manufactured by Sinovac Research and Development Co., Ltd.The main purpose of this study is to measure vaccine effectiveness of homologous…
- Trial name
- NCT05367895
- Testing
- COVID-19 Vaccine (Vero Cell), Inactivated
- Where
- Brazil
- Volunteers
- 14,000 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
Covid19
Study of the Commercial Scale SARS-CoV-2 Vaccine Against the Pilot Scale Among Adults, and Bridging Study of the Immunogenicity in Elderly Against That in Adults
This study is a randomized, double-blinded clinical Trial, to evaluate the non-inferiority of the commercial scale Inactivated SARS-CoV-2 vaccine against that of the pilot scale among adults aged 26-45 years, and the…
- Trial name
- NCT04617483
- Testing
- Two doses of commercial scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14, Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14, Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 in elderly
- Where
- China
- Volunteers
- 1,040 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
COVID-19 Pandemic
Fourth COVID-19 Vaccine Dose- mRNA1273
The Omicron variant of concern (VOC) is currently rapidly spreading worldwide, with extremely high transmission rates, with an estimated R of >3.
- Trial name
- NCT05230953
- Testing
- mRNA1273 vaccine
- Where
- Israel
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Sheba Medical Center
COVID-19
Conversation With Family Doctor to Increase COVID-19 Vaccine Uptake
The investigators will randomise individuals from family doctors' lists of patients that are at risk of severe Coronavirus Disease 2019 (COVID-19), and that are not registered as having taken the vaccine against the disease.
- Trial name
- NCT05207137
- Testing
- Telephone call about vaccination
- Where
- Norway
- Volunteers
- 654 people, healthy volunteers welcome
- Sponsor
- Norwegian Institute of Public Health
COVID-19 Vaccines
Randomized, Single-blinded, Multicenter Trial Comparing the Immune Response to a 2nd Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNTech) or Sanofi /GSK B.1.351 Adjuvanted Vaccine in Adults
The effectiveness of COVID-19 vaccines in reducing the risk of severe COVID-19 is currently demonstrated. In France, since the beginning of the vaccination campaign, 54,266,859 people have received at least one injection (ie.
- Trial name
- COVIBOOSTAnci1 (NCT05405283)
- Testing
- 2nd booster with Comirnaty® (Pfizer-BioNTech), CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK
- Where
- France
- Volunteers
- 189 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Covid19 Vaccine
Investigating the Role of 13cis Retinoic Acid in the Treatment of COVID-19 and Enhancement of Its Spike Protein Based Vaccine Efficacy and Safety.
Investigating the role of 13cis retinoic acid in the treatment of COVID-19 and enhancement of Its spike protein based vaccine efficacy and safety.
- Trial name
- Isotretinoin (NCT04730895)
- Testing
- Oral 13 cis retinoic acid, Aerosolized 13 cis retinoic acid, 13 cis retinoic acid doses orally in combination with spike protein based vaccine
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Kafrelsheikh University
COVID-19
A Blood Collection Study to Assess the Immunogenicity of Nationally Authorized Homologous COVID-19 Booster Vaccines Among Adult Vaccinees.
The purpose of this study is to assess the immunogenicity of nationally available pre-defined homologous booster vaccination of a SARS-CoV-2 WHO EUA qualified vaccination in adults aged 18 years and older
- Trial name
- NCT05710289
- Testing
- Immune Responses
- Volunteers
- healthy volunteers welcome
- Sponsor
- SK Bioscience Co., Ltd.
COVID-19
A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector)
This is a phase II, randomised, double-blinded and placebo-controlled clinical trial in healthy adults above 18 years of age. This clinical trial is designed to evaluate the immunogenicity and safety of Ad5-nCoV which encodes for…
- Trial name
- CTII-nCoV (NCT04341389)
- Testing
- Recombinant novel coronavirus vaccine (Adenovirus type 5 vector)
- Where
- China
- Volunteers
- 508 people, healthy volunteers welcome
- Sponsor
- Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China
SARS-CoV-2
Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19
The goal of this study is to assess serious adverse events associated with hospitalizations in the non-acute phase after vaccination with the mRNA-1273 vaccine in persons with underlying diseases who are considered to have a high…
- Trial name
- NCT05894590
- Where
- Japan
- Volunteers
- 13,680 people
- Sponsor
- ModernaTX, Inc.
Sars-CoV-2 Infection
Effectiveness Evaluation of the Sinopharm Vaccine in the Dondo District in Mozambique
Three complementary activities will be implemented:1) Baseline and repeat census of the catchment population; described in a separate protocol (IVI-ECOVA-03-WS1); 2) Enhanced surveillance for COVID-19 disease, and 3)…
- Trial name
- NCT05362682
- Testing
- Sinopharm Vaccine
- Where
- Mozambique
- Volunteers
- 3,000 people
- Sponsor
- International Vaccine Institute
COVID-19, Influenza
Effectiveness of An Influenza/COVID-19 Vaccine (mCombriax [mRNA-1083]) in Adults ≥ 65 Years
The purpose of this pragmatic randomized trials is to evaluate the comparative vaccine effectiveness (cVE) of mCombriax® (mRNA-1083) versus same day co-administration of the active comparators (i.e., high-dose influenza…
- Trial name
- DAN-COMBO (NCT07790523)
- Testing
- mCombriax® (mRNA-1083), Efluelda® (TIV-HD) and Spikevax® (mRNA-1273)
- Where
- 3 sites in Denmark, Spain
- Volunteers
- 410,000 people, healthy volunteers welcome
- Sponsor
- Tor Biering-Sørensen
Covid19, Vaccine Refusal
Use of Construal Level Theory to Inform Messaging to Increase Vaccination Against COVID-19
This study aims to increase uptake of the COVID booster vaccine through messaging informed by Construal Level Theory. Patients in the Mass General Brigham (MGB) health system aged 18 and older who are eligible for the COVID…
- Trial name
- NCT04871776
- Testing
- Messaging informed by construal level theory, Usual Care
- Where
- United States
- Volunteers
- 3,671 people
- Sponsor
- Brigham and Women's Hospital
SARS-CoV-2
GLS-5310 Vaccine for the Prevention of SARS-CoV-2 (COVID-19)
This clinical trial will evaluate the safety, tolerability and immunogenicity of GLS-5310 DNA vaccine against SARS-CoV-2(COVID-19) in healthy volunteers.
- Trial name
- NCT04673149
- Testing
- GLS-5310
- Where
- South Korea
- Volunteers
- 171 people, healthy volunteers welcome
- Sponsor
- GeneOne Life Science, Inc.
COVID-19
Efficacy, Safety and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)(Recov)
This is a multicenter designed Phase III clinical trial. About 10000 participants plan to be enrolled.The objectives of this study are to evaluate the efficacy, safety and immunogenicity of the recombinant two-component COVID-19…
- Trial name
- NCT05398848
- Testing
- Recombinant two-component COVID-19 vaccine (CHO cell)
- Where
- 11 sites in Nepal, Russia
- Volunteers
- 7,623 people, healthy volunteers welcome
- Sponsor
- Jiangsu Rec-Biotechnology Co., Ltd.
COVID-19 Pandemic
A PhaseⅡ Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-19 Vaccine
This study is a randomized, double-blind, placebo-controlled Phase II clinical trial to evaluate the safety and immunogenicity of SCTV01E in population of different ages who have been vaccinated against COVID-19.
- Trial name
- SCTV01E (NCT05652543)
- Testing
- SCTV01E
- Where
- 4 sites in China
- Volunteers
- 518 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Breastfeeding, COVID-19 Infection
Researchers At UC San Diego Are Learning About the Benefits of Human Milk and How It Influences Infant and Child Health
The purpose of the UCSD Human Milk Biorepository is to establish and maintain a repository of breast milk samples that can be used to learn more about how breast milk influences infant and child health.
- Conditions
- Breastfeeding, COVID-19 Infection, COVID-19 Vaccine, Remdesivir
- Trial name
- NCT05553743
- Testing
- COVID-19 Exposure, Antibiotic
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
COVID-19, Vaccine Adverse Reaction
Evaluation of the Immunogenicity and Safety BBIBP-CorV Vaccine for COVID-19 in Adults in Guinea
Phase II, non-randomized, open-label, comparative, single center national trial in Guinea, aimed to assess the humoral vaccine immune response induced by BBIBP-CorV vaccine in 200 adults aged between 18 and 45 years or 55 or…
- Conditions
- COVID-19, Vaccine Adverse Reaction, Sars-CoV-2 Infection, Healthy Volunteer
- Trial name
- CovicompareG (NCT05409300)
- Testing
- BBIBP-CorV
- Where
- 2 sites in Guinea
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Covid-19, Vaccine
Immunogenicity of COVID-19 Vaccine on Heterologous Schedule
This is a prospective, single blinded randomized homologous/heterologous prime-boost vaccine clinical study, designed to assess the immunogenicity of heterologous prime-boost immunization with AZD1222 and MVC-COV1901 in adults.
- Conditions
- Covid-19, Vaccine, Immunogenicity, Reactogenicity
- Trial name
- NCT05054621
- Testing
- Heterologous prime-boost schedule with AZD1222 and MVC-COV1901, Homologous prime-boost schedule with two doses of AZD1222
- Where
- Taiwan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.